Interestingly, for the first time, we showed low FOXM1 activity in AML patients with NPMmut and that low FOXM1 activity is an independent predictor of chemotherapy response and disease-free survival for AML patients (25). This evidence concerns the gene FOXM1 and acute myeloid leukemia.